Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report published on Wednesday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.40 on Wednesday. Oragenics has a 12 month low of $0.38 and a 12 month high of $7.74. The company has a market capitalization of $1.78 million, a P/E ratio of -0.05 and a beta of 0.50. The company’s 50 day simple moving average is $0.92 and its 200 day simple moving average is $1.26.

Oragenics (NYSE:OGEN) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new stake in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is currently owned by hedge funds and other institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.